HighTower Advisors
LCTX icon

HighTower Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

HighTower Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$100K Buy
104,870
+5,000
+5% +$5.53K ﹤0.01% 3682
2026
Q2 		$131K Hold
99,870
– – ﹤0.01% 3618
2026
Q1 		$158K Buy
99,870
+1,500
+2% +$2.53K ﹤0.01% 3554
2025
Q4 		$164K Hold
98,370
– – ﹤0.01% 3419
2025
Q3 		$166K Buy
98,370
+40,664
+70% +$48.1K ﹤0.01% 3423
2025
Q2 		$52.4K Hold
57,706
– – ﹤0.01% 3544
2025
Q1 		$26.1K Hold
57,706
– – ﹤0.01% 3502
2024
Q4 		$29K Buy
57,706
+19,100
+49% +$14K ﹤0.01% 3509
2024
Q3 		$35K Sell
38,606
-17,065
-31% -$15.8K ﹤0.01% 3455
2024
Q2 		$56K Sell
55,671
-8,300
-13% -$9.17K ﹤0.01% 3293
2024
Q1 		$95K Buy
63,971
+9,900
+18% +$11.2K ﹤0.01% 3161
2023
Q4 		$59K Hold
54,071
– – ﹤0.01% 3277
2023
Q3 		$64K Buy
54,071
+19,955
+58% +$27.1K ﹤0.01% 3189
2023
Q2 		$48K Sell
34,116
-16,000
-32% -$22.1K ﹤0.01% 3168
2023
Q1 		$75K Buy
50,116
+16,000
+47% +$22.3K ﹤0.01% 2991
2022
Q4 		$40K Buy
34,116
+700
+2% +$882 ﹤0.01% 3065
2022
Q3 		$37K Hold
33,416
– – ﹤0.01% 2918
2022
Q2 		$53K Hold
33,416
– – ﹤0.01% 2900
2022
Q1 		$51K Hold
33,416
– – ﹤0.01% 3067
2021
Q4 		$82K Buy
33,416
+100
+0.3% +$234 ﹤0.01% 2956
2021
Q3 		$84K Buy
33,316
+17,000
+104% +$43.6K ﹤0.01% 2866
2021
Q2 		$46K Hold
16,316
– – ﹤0.01% 2900
2021
Q1 		$38K Hold
16,316
– – ﹤0.01% 2858
2020
Q4 		$28K Buy
+16,316
New +$22.8K ﹤0.01% 2458

Other funds holding LCTX

Defender Capital
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return
Hofer & Associates
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
Red Crane Wealth Management
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

HighTower Advisors's LCTX Position: Q3 2026 in Review

HighTower Advisors increased its Lineage Cell Therapeutics (LCTX) stake by 5% in Q3 2026, buying an estimated $5.53K and bringing the position to 104,870 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

HighTower Advisors first reported a position in LCTX in Q4 2020 and has held it in 24 quarters since. The position peaked at $166K in Q3 2025. 64 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • HighTower Advisors held 104,870 shares of Lineage Cell Therapeutics worth $100K as of Q3 2026.
  • HighTower Advisors bought 5,000 Lineage Cell Therapeutics shares in Q3 2026, an estimated $5.53K.
  • Lineage Cell Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3682 holding.
  • HighTower Advisors first reported a position in Lineage Cell Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • HighTower Advisors's Lineage Cell Therapeutics position peaked at $166K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.